Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Suspected adverse reactions following chimeric ...

"Although CAR-T products have to date been associated with fewer cancers than products made with the previous generation of viruses used for gene therapy transduction, the potential for ...

CAR T cell exhaustion and differentiation were studied using an in vitro exhaustion ... Polybrene (6ug/ml) and hIL-2 (50U/ml) were added to the supernatants and cells were spin-transduced at 1300g for ...

Yescarta – a CD19-directed genetically modified autologous T-cell immunotherapy investigated in the ZUMA-1 trial – is the first chimeric antigen receptor (CAR) T-cell therapy recommended for ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases. By selectively depleting CD19-positive B-cells, ...

Copyright: © 2025 Elsevier Ltd. Published by Elsevier Ltd. CAR T-cell therapies have revolutionised treatment of many diseases, but their expense means many patients ...

Like other CAR-Ts, Calibr's therapy is manufactured from a patient's own T-cells, which are harvested and genetically modified to fight cancer before being reintroduced into the body.

CAR T cells show contrasting approaches to killing cancer, with one sprinting for fast action and the other collaborating for endurance. Scientists are now focusing on adapting these cells to outsmart ...